A Closer Look at 11 Analyst Recommendations For Intra-Cellular Therapies
Intra-Cellular Therapies (NASDAQ:ITCI) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 4 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 1 | 0 | 0 |
| 2M Ago | 3 | 2 | 0 | 0 | 0 |
| 3M Ago | 2 | 1 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $99.18, a high estimate of $120.00, and a low estimate of $78.00. This current average has increased by 1.96% from the previous average price target of $97.27.
Breaking Down Analyst Ratings: A Detailed Examination
A comprehensive examination of how financial experts perceive Intra-Cellular Therapies is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Ami Fadia | Needham | Raises | Buy | $100.00 | $94.00 |
| Ashwani Verma | UBS | Lowers | Neutral | $83.00 | $85.00 |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $103.00 | $103.00 |
| Graig Suvannavejh | Mizuho | Raises | Buy | $100.00 | $96.00 |
| Sumant Kulkarni | Canaccord Genuity | Raises | Buy | $113.00 | $107.00 |
| Ami Fadia | Needham | Raises | Buy | $94.00 | $90.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $120.00 | $120.00 |
| Jessica Fye | JP Morgan | Raises | Overweight | $78.00 | $75.00 |
| Ami Fadia | Needham | Maintains | Buy | $90.00 | $90.00 |
| Ami Fadia | Needham | Maintains | Buy | $90.00 | $90.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $120.00 | $120.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Intra-Cellular Therapies. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Intra-Cellular Therapies compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Intra-Cellular Therapies's stock. This analysis reveals shifts in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Intra-Cellular Therapies's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Intra-Cellular Therapies analyst ratings.
Get to Know Intra-Cellular Therapies Better
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Intra-Cellular Therapies: Financial Performance Dissected
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Intra-Cellular Therapies displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 52.9%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Intra-Cellular Therapies's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -10.53%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Intra-Cellular Therapies's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -2.56%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Intra-Cellular Therapies's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.07%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.03, Intra-Cellular Therapies adopts a prudent financial strategy, indicating a balanced approach to debt management.
How Are Analyst Ratings Determined?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.